Full-Time

Senior Administration and Co-Pay Associate

Posted on 5/9/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Remote in Canada

Remote

Category
Operations & Logistics (1)
Required Skills
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • A University Degree in a related field or equivalent an asset
  • A minimum of two (2) years’ experience in customer service; experience in medical, pharmaceutical and/or insurance industry is an asset
  • Bilingual in French and English: written and verbal
  • Highly organized with strong attention to detail
  • Strong proficiency in Microsoft applications (Outlook, Word, Excel & PowerPoint)
  • Flexibility in working shifts (hours of operation are 8 am - 8pm)
  • Strong critical thinking and problem-solving abilities
  • A Minimum of 2 years’ experience working for a patient support program
  • Strong communication and interpersonal skills, written and verbal including effective phone etiquette to diverse audiences i.e. internal, healthcare professionals and patients
  • Proven ability to manage time, set priorities and multi-task in order to meet various competing work deadlines
  • Demonstrates a strong work ethic, is reliable and shows initiative to purse new skills
  • Advanced knowledge of pharmaceutical distribution industry
  • Strong business and financial acumen
  • Strong analytical and mathematical skills
  • Ability to work in a fast-paced environment and consistently meet deadlines
  • Phone etiquette to diverse audiences i.e. internal, healthcare professionals and patients
  • Effective interpersonal and leadership skills
  • Effective organizational skills; attention to detail
  • Strong Knowledge of Microsoft Word, Excel, PowerPoint and other Office Programs
  • Strong knowledge of patient support programs
  • Excellent people skills, teamwork, empathy, influencing others, adaptability
  • Strong knowledge of Microsoft Word, Excel, PowerPoint and other Office Programs
  • Knowledge of Microsoft Word, Excel, PowerPoint and other Office Programs
  • Excellent presentation skills
  • Knowledge of Microsoft Word, Excel, PowerPoint and other Office Programs
  • Knowledge of patient support programs
  • Excellent problem-solving skills: ability to resolve issues effectively and efficiently
  • Knowledge of Microsoft Word, Excel, PowerPoint and other Office Programs
Responsibilities
  • Assist with the coaching and mentoring of the existing team members.
  • Work with APM/PM to maintain, improve and create work standards and standardized work.
  • Performs general administrative tasks such as handling the mail, typing, and maintenance of filing systems for the program
  • Process payment requests for patients, pharmacies and/or physicians.
  • Participate in special projects as assigned by the APM/PM
  • Provide daily support to the APM(s)/PM
  • Assist management with various reports and program related tasks.
  • Work with management to develop program protocol and SOP for administrative and co-pay work.
  • Work with management to develop and lead training of new associates, including but not limited to presenting, shadowing and call monitoring.
  • Liaise with program managers to ensure co-payment KPIs are met.
  • Liaise with cross-functional teams to ensure payment accuracy and timelines are met.
  • Adherence to the general company processes and policies.
  • Telephone Support - Phone line monitoring for availability, correct status and reporting.
  • Participate and attend on-going refresher trainings and in specialized training courses for specific products, programs and purposes as deemed appropriate by the manager.
  • Clear communication to APM/PM and program regarding cases of planned and unforeseen absences.
  • The Senior Administration and Co Pay associate will also be assigned other duties and tasks as required and deemed necessary by management

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Cencora who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.